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) was referred to gynecology clinic with chief complaints of abdominal distension and localized
abdominal wall pruritus for three months. She was misdiagnosed with gastrointestinal disorder and ultimately had undergone
imaging. Ultrasonography and computed tomography (CT) scan disclosed a huge solid-cystic mass originating from the ovary. On
clinical examination the patient had no pain or tenderness and no gynecologic complaints. Laboratory tests showed normal tumor
markers and hemoglobin at 8 g/dl. Laparotomy was carried out as diagnosis of ovarian serous cyst adenoma, but a huge tumor
with attachment to uterus and ovaries and extension to pelvic floor, peripheral tissues of ureter, and upper abdomen was found.
Hysterectomy with bilateral salpingooophorectomy was done. Pathology report demonstrated uterine leiomyosarcoma measuring
40 centimeters and weighing 10 kilograms. In conclusion, as pelvic masses even in a large size may present unspecific symptoms
misdiagnosis may occur which lead to overgrowth, local invasion, or other complications. So, it is rather to suggest ultrasonography
in patients with persistent abdominal or pelvic symptoms and if needed, more exact diagnostic modalities like magnetic resonance
imaging (MRI) could be offered to avoid misdiagnosis and mismanagement.
1. Introduction
Pelvic masses are common findings in general gynecology
[1]. Benign leiomyomas are the most uterine neoplastic mass
which manifest clinically in about 30% of women older than
35 years [2]. Uterine sarcomas include 8% of all uterine
malignancies with an incidence of about 0.4 per 100,000
women where leiomyosarcoma (LMS) consists 40% of them
[3]. It occurs mostly in the 45–55 years of age. Leiomyosar-
comas usually arise de novo from uterine smooth muscles;
however rarely they may appear in a preexisting leiomyoma
(0.2% of the cases) [4]. The gold standard of treatment
for LMS is hysterectomy [5, 6]. Most leiomyosarcomas are
accompanied with pain, sensation of pressure, and abnormal
uterine bleeding or present only as a rapidly enlarging mass
[7]. However, many imagingmodalities are available and easy
to accelerate the diagnosis; still some gigantic tumors are
going to be neglected. Moreover, sometimes these tumors are
erroneously reported as ovarian masses on imaging follow-
up which can induce severe challenges for surgeon during
operation. Herein we represent a huge uterine leiomyosar-
coma mismanaged with incorrect diagnosis of dyspepsia for
over two months and afterwards operated as misdiagnosis of
ovarian mass reported in images.
2. Case Presentation








) was referred to gynecol-
ogy clinic with chief complaints of abdominal distension and
localized abdominal pruritus for three months. To rule out
gastrointestinal disorders, she had visited a general physician
given her symptoms. But she found no response to the
drugs in spite of a long-term usage and was referred to
our clinic after taking ultrasonography. Her past history
showed menorrhagia but not menstrual irregularity and
dysmenorrhea for several months. Laboratory tests including
hemoglobin at 8 g/dl, hematocrit at 28,7%, ferritin at 6 ng/ml,
and iron at 29mcg/dl approved this claim but the patient
had not expressed it initially as a complaint. Vital signs
were in normal limits. In general appearance, the patient
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Figure 1: Intravenous contrast CT scan showing a large septated
solid-cystic mass with report of serous cyst adenoma.
was not cachectic with full activity without vertigo, impair-
ing appetite, constipation, nausea, vomiting, and urinary
symptoms, but a distended abdomen that lacks rebound and
tenderness. The origin of the mass was not detectable by
vaginal examination. Ultrasonography had revealed a huge
multicystic septated mass, 40 cm in diameter in abdominal
cavity, probably a serous cystadenoma originating fromovary
that was extended to epigastric area. Uterine and bladder
were reported normal; however, these were impressed by
extrinsic pressure of the mass. Uterine observation was not
possible with vaginal sonography due to huge ovarian tumor.
Tumor markers including cancer antigen-125, carcinoem-
bryonic antigen, 𝛼FP, and CA19-9 were all within normal
limits. Further assessment by computed tomography (CT)
scan was done to show the nature of tumor which approved
the diagnosis of ovarian serous cyst adenoma (Figure 1);
other viscera like kidneys, spleen, and liver were all in
normal status; no free fluid and no lymphadenopathy were
observed in abdominal cavity. Chest X-ray also did not
show any lesion. The patient was hospitalized and advised
with operation. The surgery was performed under general
anesthesia through a vertical incision. Laparotomy revealed
a huge multilocular mass with firm consistency, originating
from pelvic with extension to adjacent tissues like ureter and
upward to diaphragm with adhesion to ovaries and uterine.
Obviously, gentle adhesiolysis to avoid damage to ureter and
intestine took a long time.Thewhole solid-multicystic tumor
measuring 40 cm and weighing 10 kg and with attached
uterine and ovaries was removed (Figure 2). Lymph nodes
and other visceral organs were normal. Regarding previous
chronic anemia of the patient, transfusion of two-packed cell-
blood was done. Patient’s weight was 82 kg before operation
and 69 kg subsequently. Three days later, the patient was
discharged in a good health status. Pathology report showed
uterine leiomyosarcoma (Figure 3). The CT scan for patient’s
follow-up presents no metastatic mass and lymph node
involvement. The patient is under observation and has no
problem in one year.
3. Discussion
Leiomyosarcomas (LMS) are the most common sarcomatous
malignancies of uterus that represent 1-2% of all uterine
Figure 2: Gross appearance of tumor.
Figure 3: Microscopic appearance of tumor cells.
malignancies [8, 9]. Most patients with leiomyosarcoma have
no recognizable risk factors. Patients who carry a germ
line p53 gene mutation (Li-Fraumeni syndrome) have an
increased risk of soft tissue cancers, including uterine LMS
[10]. Some studies have suggested an increased risk for uterine
sarcoma among women with obesity and also diabetes [11].
Our case had no identifiable risk factor except her BMIwhich
was 27 kg/m2.
The absolute diagnosis of uterine leiomyosarcoma is
made by histologic confirmation. Inmost cases, the diagnosis
of these tumors is made by specimen examination in hys-
terectomized patientswhowasmanaged as leiomyoma [5, 12].
The main treatment of LMS is surgical excision which
consists of total abdominal hysterectomy and debulking of
any tumor invading outside the uterus. It is considered
appropriate to preserve ovaries in young women and routine
dissection of pelvic and para-aortic lymphnodes, since lymph
node involvement is seen in less than 3% of patients [13]. Its
five-year survival rate varies from 18.8% to 68% and the risk
of recurrence is reported from 45% to 73% [4]. As sarcomas
are very aggressive tumors and have the propensity for early
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hematogenous spread, recurrence and relapse can occur even
in completely resected tumors. So it is recommended to
prescribe adjuvant chemotherapy in nonmetastatic cases by
some authors. The utility of systemic lymph node dissection
and adjuvant radiotherapy (RT) in the treatment of uterine
LMS remains unclear. Although radiotherapy for reduction of
local recurrence and/or chemotherapy for managing distant
metastasis have been stated, the literature shows no efficacy
concerning overall survival by thesemodalities actually. Any-
way, attention to quality of life which may be influenced by
the side effects and toxicity of adjuvant therapy is mandatory
[8, 14]. Most cases include women over 40 years old, who are
usually referred with abnormal vaginal bleeding (56%), pal-
pable pelvic mass (54%), and pelvic pain (22%) [15]. Kaur et
al. reported postmenopausal bleeding and lower abdominal
pain in a 60-year-old female with uterine leiomyosarcoma
while our patient had no gynecologic problem and no pain
[8]. Senol et al. reported a very large leiomyosarcoma in a
62-year-old female presenting with abdominal mass, fatigue,
and associated tenderness [16]. Vellanki et al. also reported a
uterine leiomyosarcoma in a 40-year-old nulliparous woman
presenting with abdominal pain and no menstrual irreg-
ularity and no vaginal bleeding [17]; our patient had no
vaginal bleeding and no abdominal pain, just complains
from 3 months’ period of abdominal distension attributed
to gastrointestinal diseases. However, abdominal distension
is usually attributed to gastrointestinal diseases which leads
to misdiagnosis, mismanagement, and overgrowth of tumor
[18]. So, it would be reasonable to take an exact history to
find out associated symptoms like menorrhagia seen in our
case. Besides obtaining a complete history, physical exam-
ination, advising appropriate laboratory tests and imaging
procedures, is very mandatory particularly in patients who
do not respond to usual medications. In this case, severe
anemia could be regarded as an alarm sign for her physician
if detected. Ultrasonography is considered more appropriate
as the first modality for detection of abdominopelvic mass,
because it is harmless, available, inexpensive, and applica-
ble by all radiologists and many gynecologists. It cannot
reliably determine the origin of huge masses, the nature of
malignancy point, and probable invasion of adjacent organs.
The role of magnetic resonance imaging (MRI) is developing
in the assessment of malignancies. leiomyosarcomas com-
monly manifest as large infiltratingmyometrial mass onMRI
with irregular and ill-defined margins and heterogeneous
hypointensity on T1-weighted images and also hemorrhage,
necrosis, and foci of calcifications may make heterogeneous
features of enhancement which can be a hallmark for dif-
ferentiating from benign leiomyomas [4, 19]. Researchers
believe that the sensitivity of MRI for distinguishing the
nature and origin of pelvic masses is more than CT scan
[4, 20]. To verify, CT scan determined the abovementioned
characteristics of the mass in our case but could not define its
origin correctly. Subsequently, the patient was operated with
diagnosis of ovarian serous cyst adenoma. However, themain
advantage of CT scan is that it is cheaper thanMRI and more
tolerable for patients [4, 20].
In conclusion, pelvic masses even in a large size may be
without any specific symptoms. Delay in diagnosis may lead
to overgrowth, torsion, or hemorrhagic tear of tumors and
invasion to surrounding visceral organs. So, it is considered
more appropriate to suggest ultrasonography in patients
with persistent abdominal pain or distension who do not
respond to recommended drugs and in case of presence of
a mass, MRI as a preferable imaging could be offered to avoid
misdiagnosis.
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